Biologics Tech Transfer & Validation at Scale: A Better Path to GMP

As biologics programs advance from development into clinical and commercial manufacturing, the stakes of tech transfer and validation rise sharply. Increasing molecular complexity, compressed timelines, and site-specific differences leave little room for misalignment. Process understanding built at development scale does not always translate cleanly to GMP operations, and gaps often emerge when equipment, facilities, data interpretation, or control strategies are not fully aligned.

This on-demand session focuses on the points where tech transfer, scale-up, and validation most often break down — and how experienced teams work to prevent those failures. It examines how variability is introduced across sites and scales, why issues may appear late in the lifecycle, and what it takes to sustain confidence heading into PPQ. Attendees will gain practical insight into transferring both process and analytical knowledge, establishing qualified scale-down models, and structuring data handoffs that support consistent performance.

The discussion also addresses stage-appropriate process characterization, validation lifecycle expectations, and the role of comparability and method transfer in overall GMP readiness. For teams preparing to scale, success depends not just on having a strategy, but on executing it with discipline.

Watch on demand to strengthen readiness as programs progress toward commercial reality.